Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

This biotech innovator, known for its royalty-driven model, reported a notable insider sale amid a period of strong share ...

Ligand Announces 2026 Investor Day in New York City

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on ...

Ligand Pharmaceuticals Incorporated

View Ligand Pharmaceuticals Incorporated LGND stock quote prices, financial information, real-time forecasts, and company news from CNN.
The Motley Fool

This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know

This sell reduced Ligand Pharmaceuticals from 5.8% to 4.8% of Ashford Capital Management’s 13F reportable AUM. Top holdings after the filing: NASDAQ:GSAT: $51.3 million (5.7% of AUM) NASDAQ:LGND: ...
Business Wire

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration ...
Phys.org

Ligand engineering method streamlines design for chemical reactions in catalysis and drug delivery

Researchers at Hokkaido University in Japan have developed a technique called Virtual Ligand-Assisted Optimization, or VLAO, to enhance the design and effectiveness of ligands, which are important ...
Seeking Alpha

Ligand Pharmaceuticals: 2026 Guidance May Already Be Included In Current Valuation

Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio. LGND expects royalty revenue to compound at a 23% CAGR through ...